51
|
Handa O, Majima A, Onozawa Y, Horie H, Uehara Y, Fukui A, Omatsu T, Naito Y, Yoshikawa T. The role of mitochondria-derived reactive oxygen species in the pathogenesis of non-steroidal anti-inflammatory drug-induced small intestinal injury. Free Radic Res 2014; 48:1095-9. [PMID: 24870068 DOI: 10.3109/10715762.2014.928411] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) have been implemented in clinical settings for a long time for their anti-inflammatory effects. With the number of NSAID users increasing, gastroenterological physicians and researchers have worked hard to prevent and treat NSAID-induced gastric mucosal injury, an effort that has for the large part being successful. However, the struggle against NSAID-induced mucosal damage has taken on a new urgency due to the discovery of NSAID-induced small intestinal mucosal injury. Although the main mechanism by which NSAIDs induce small intestinal mucosal injury has been thought to depend on the inhibitory effect of NSAIDs on cyclooxygenase (COX) activity, recent studies have revealed the importance of mitochondria-derived reactive oxygen species (ROS) production, which occurs independently of COX-inhibition. ROS production is an especially important factor in the increase of small intestinal epithelial cell permeability, an early stage in the process of small intestinal mucosal injury. By clarifying the precise mechanism, together with its clinical features using novel endoscopy, effective strategies for preventing NSAID-induced small intestinal damage, especially targeting mitochondria-derived ROS production, may be developed.
Collapse
|
52
|
Gould A, Udalski A, Shin IG, Porritt I, Skowron J, Han C, Yee JC, Kozłowski S, Choi JY, Poleski R, Wyrzykowski Ł, Ulaczyk K, Pietrukowicz P, Mróz P, Szymański MK, Kubiak M, Soszyński I, Pietrzyński G, Gaudi BS, Christie GW, Drummond J, McCormick J, Natusch T, Ngan H, Tan TG, Albrow M, DePoy DL, Hwang KH, Jung YK, Lee CU, Park H, Pogge RW, Abe F, Bennett DP, Bond IA, Botzler CS, Freeman M, Fukui A, Fukunaga D, Itow Y, Koshimoto N, Larsen P, Ling CH, Masuda K, Matsubara Y, Muraki Y, Namba S, Ohnishi K, Philpott L, Rattenbury NJ, Saito T, Sullivan DJ, Sumi T, Suzuki D, Tristram PJ, Tsurumi N, Wada K, Yamai N, Yock PCM, Yonehara A, Shvartzvald Y, Maoz D, Kaspi S, Friedmann M. Exoplanet detection. A terrestrial planet in a ~1-AU orbit around one member of a ~15-AU binary. Science 2014; 345:46-9. [PMID: 24994642 DOI: 10.1126/science.1251527] [Citation(s) in RCA: 94] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Using gravitational microlensing, we detected a cold terrestrial planet orbiting one member of a binary star system. The planet has low mass (twice Earth's) and lies projected at ~0.8 astronomical units (AU) from its host star, about the distance between Earth and the Sun. However, the planet's temperature is much lower, <60 Kelvin, because the host star is only 0.10 to 0.15 solar masses and therefore more than 400 times less luminous than the Sun. The host itself orbits a slightly more massive companion with projected separation of 10 to 15 AU. This detection is consistent with such systems being very common. Straightforward modification of current microlensing search strategies could increase sensitivity to planets in binary systems. With more detections, such binary-star planetary systems could constrain models of planet formation and evolution.
Collapse
|
53
|
Matsuda C, Danno K, Miyazaki S, Fujitani K, Kubota M, Kawada J, Takagi M, Fukui A, Iwase K, Tanaka Y. [Tolerability of XELOX in postoperative adjuvant chemotherapy for colorectal cancer]. Gan To Kagaku Ryoho 2014; 41:743-747. [PMID: 25129086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
A regimen of capecitabine plus oxaliplatin(XELOX)has become one of the standard postoperative adjuvant chemotherapies for colon cancer. However, few tolerability studies have been conducted in Japan. In this study, we retrospectively examined treatment continuation and the adverse events that occurred during 8 courses of postoperative adjuvant chemotherapy with XELOX in 21 patients with colorectal cancer who had undergone curative resection. The completion rate for 8 courses of treatment with XELOX was 71.4%, while the median relative dose intensities of capecitabine and oxaliplatin were 85.0% and 75.0%, respectively. Although the incidence of subsequent Grade 3 or higher hand-foot syndrome was 14.3%, the rate of peripheral neuropathy was 0%. Our hospital had a high rate of XELOX treatment continuation, suggesting that XELOX adjuvant chemotherapy would be well tolerated in clinical practice as well.
Collapse
|
54
|
Ohta K, Ishida Y, Fukui A, Nishi H, Naruse T, Takechi M, Kamata N. Itraconazole inhibits TNF‐α‐induced CXCL10 expression in oral fibroblasts. Oral Dis 2014; 21:106-12. [DOI: 10.1111/odi.12226] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2013] [Revised: 12/24/2013] [Accepted: 01/23/2014] [Indexed: 01/31/2023]
|
55
|
Hamamoto Y, Inata H, Kataoka M, Fukui A, Urashima Y, Matsuki H, Uwatsu K, Ochi T, Watanae Y, Mochizuki T. EP-1271: Institutional difference of radiotherapy for esophageal cancer in core hospitals for cancer medical care. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)31389-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
56
|
Nishikawa K, Iwase K, Aono T, Yoshida H, Nomura M, Tamagawa H, Matsuda C, Deguchi T, Kawada J, Higashi S, Deguchi K, Noguchi Y, Okumura Y, Nomura M, Fushimi H, Takagi M, Fukui A, Fujitani K, Endo S, Tanaka Y. [A case of paclitaxel-resistant recurrent gastric cancer responsive to S-1 plus docetaxel]. Gan To Kagaku Ryoho 2013; 40:2259-2261. [PMID: 24394078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
We report the case of a patient with paclitaxel (PTX) -resistant recurrent gastric cancer who was effectively treated with S-1 plus docetaxel( DOC). A 62-year-old woman underwent total gastrectomy for Stage IV advanced gastric cancer (type 4, por 2>sig, pT4a (SE), pN3a, pP1, CY1) in 2009. Although S-1 was administered as first-line chemotherapy, recurrent peritoneal metastasis was diagnosed 22 months after surgery. S-1 plus irinotecan (CPT-11) was administered as second-line chemotherapy, and this was followed by weekly PTX (80 mg/m2) as third-line chemotherapy. However, computed tomography (CT) showed increased ascites and peritoneal wall thickening in the pelvis. As the tumor proved resistant to PTX, making the treatment ineffective, S-1( 80 mg/m2, day 1-14, q3w) plus DOC( 40 mg/m2, day 1, q3w) was initiated. Two months later, the ascites and peritoneal wall thickening in the pelvis disappeared. Twelve months after initiation of S-1 plus DOC chemotherapy, no sign of recurrence has been noted.
Collapse
|
57
|
Kawada J, Nishimura M, Matsui Y, Nomura M, Noguchi Y, Okumura Y, Danno K, Kubota M, Matsuda C, Omori K, Nishikawa K, Nomura M, Takagi M, Fukui A, Fujitani K, Iwase K, Tanaka Y. [Analysis of weekly paclitaxel chemotherapy for esophageal cancer]. Gan To Kagaku Ryoho 2013; 40:2118-2120. [PMID: 24394032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
PURPOSE Public knowledge-based application for paclitaxe(l PAC) has been approved for advanced or recurrent esophageal cancer. We investigated the feasibility of weekly PAC chemotherapy as a second-line or subsequent regimen for metastatic or recurrent esophageal cancer. MATERIALS AND METHODS Patients received PAC( 100 mg/m2 intravenously) on days 1, 8, 15, 22, 29, and 36 of each 8-week period. We analyzed the toxicity and efficacy in 6 patients treated with the weekly PAC chemotherapy. RESULTS Grade 3-4 toxicities were neutropenia, leukopenia, and anemia. Two patients had stable disease and 2 had progressive disease. CONCLUSION By managing the side effects, weekly PAC therapy is considered a feasible regimen that can be administered on an outpatient basis.
Collapse
|
58
|
Kawada J, Nishimura M, Matsui Y, Nomura M, Noguchi Y, Okumura Y, Danno K, Kubota M, Matsuda C, Omori K, Nishikawa K, Nomura M, Takagi M, Fukui A, Fujitani K, Iwase K, Tanaka Y. [Analysis of patients with gastrointestinal neuroendocrine tumor]. Gan To Kagaku Ryoho 2013; 40:2448-2450. [PMID: 24394140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
PURPOSE We investigated the background factors, histopathological results, and prognosis of patients with gastrointestinal neuroendocrine tumors. MATERIALS AND METHODS The medical records of 42 patients with gastrointestinal neuroendocrine tumors who were diagnosed and treated at our hospital from 2002 to 2012 were collected and retrospectively reviewed. RESULT The ratio of male to female patients was 29:13; the mean age was 66.1 years. The tumors were located in the esophagus( 2 patients), stomach( 13 patients), duodenum( 9 patients), colon( 1 patient), and rectum( 18 patients). Regarding the depth of the tumor, invasion of the submucosa( SM) was observed in 26 patients; invasion of the muscularis propria( MP), in 1 patient; invasion of the subserosa( SS), in 3 patients; penetration of the serosa( SE)( AD), in 1 patient, invasion of the adjacent structures( SI)( AI), in 3 patients; and the extent of tumor invasion was unknown in 1 patient. Patients who experienced relapse had a poor prognosis, and all the patients died.
Collapse
|
59
|
Deguchi K, Nishikawa K, Iwase K, Kawada J, Aono T, Yoshida H, Nomura M, Tamagawa H, Matsuda C, Deguchi T, Higashi S, Okumura Y, Noguchi Y, Nomura M, Takagi M, Fukui A, Tanaka Y. [A case of HER2-positive advanced gastric cancer successfully treated with a combination of capecitabine, cisplatin, and trastuzumab as first-line chemotherapy]. Gan To Kagaku Ryoho 2013; 40:2253-2255. [PMID: 24394076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
We report a case of human epidermal growth factor receptor(HER)2-positive advanced gastric cancer successfully treated with a combination of capecitabine, cisplatin(CDDP), and trastuzumab as first-line chemotherapy. A 66-year-old woman diagnosed as having advanced gastric cancer underwent chemotherapy after abdominal computed tomography (CT)revealed multiple metastases to the liver, lung, lymph nodes, and peritoneum. Histopathological examination indicated a type 3, tub1, cT3(SS), N3, H1, P1, M1(LYM, PUL), cStage IV gastric tumor. Because overexpression of HER2 protein was observed in primary tumor immunostaining, combination therapy of capecitabine+CDDP+trastuzumab was administered as first-line chemotherapy. After 4 courses, CT scans revealed decreased primary tumor size, liver lesion, lymph nodes, and elimination of the lung lesion, thereby suggesting a partial response(PR). The grade 3 adverse events were neutropenia, anemia, and anorexia. After discontinuation of CDDP because of elevation of serum creatinine levels, combination therapy with capecitabine and trastuzumab was continued.
Collapse
|
60
|
Nishikawa K, Iwase K, Aono T, Yoshida H, Nomura M, Tamagawa H, Matsuda C, Deguchi T, Kawada J, Higashi S, Deguchi K, Noguchi Y, Okumura Y, Nomura M, Fushimi H, Takagi M, Fukui A, Fujitani K, Endo S, Tanaka Y. [A case of advanced gastric cancer with para-aortic lymph node metastasis successfully treated with preoperative S-1/Lentinan chemotherapy followed by curative gastrectomy]. Gan To Kagaku Ryoho 2013; 40:2200-2202. [PMID: 24394059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
We report a case of advanced gastric cancer successfully treated with preoperative S-1/Lentinan (LTN)chemotherapy followed by curative gastrectomy. The patient was a 75-year-old man with right hypochondralgia. Endoscopic examination revealed a huge type 2 gastric cancer in the middle body of the stomach. Abdominal computed tomography (CT) revealed multiple perigastric lymph node metastases and bulky para-aortic lymph node metastases. The clinical diagnosis was cT 4N3M1( LYM) with cStage IV. We thought a complete resection would be difficult, so he was treated with S-1( 80 mg/m2 day 1-28/q6w) and LTN (2 mg weekly) in May 2010. After 3 courses, the primary lesion was markedly reduced, and gastric endoscopic biopsy showed no malignant lesion. After 4 courses, abdominal CT showed no lymph node swelling at the perigastric and para-aortic areas. After 5 courses, distal gastrectomy with D2 lymphadenectomy was performed. The histological diagnosis was ypT2( MP) N0M0, Stage IB. Histological features of the primary tumor and lymph nodes were judged to be Grade 2 and Grade 3, respectively. After surgery, S-1/LTN treatment was continued for 1 year. During this period, there were no serious adverse events. The patient has been in good health without recurrence for 28 months after surgery.
Collapse
|
61
|
Yoshitomi R, Fukui A, Nakayama M, Ura Y, Ikeda H, Oniki H, Tsuchihashi T, Tsuruya K, Kitazono T. Sex differences in the association between serum uric acid levels and cardiac hypertrophy in patients with chronic kidney disease. Hypertens Res 2013; 37:246-52. [PMID: 24089265 DOI: 10.1038/hr.2013.134] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2013] [Revised: 08/08/2013] [Accepted: 09/08/2013] [Indexed: 01/22/2023]
Abstract
Several studies have documented an association between serum uric acid (SUA) concentration and cardiac hypertrophy in hypertensive patients; however, the association remains unclear in chronic kidney disease (CKD) patients. If there is an association between SUA and hypertrophy in these patients, it is unknown whether the association is different between men and women. Our aim in this study is to determine whether SUA is associated with cardiac hypertrophy in CKD patients, focusing on any sex differences. Two hundred sixteen CKD patients (117 men and 99 women) were enrolled in this cross-sectional study. Patients prescribed uric acid-lowering agents and those with congestive heart failure, valvular heart disease, or ischemic heart disease were excluded from this study. Left ventricular mass index (LVMI) and left ventricular hypertrophy (LVH) were assessed using echocardiography. The prevalence of LVH was 58% in men and 47% in women. In multivariate linear regression analysis, SUA levels did not correlate with LVMI in men, whereas SUA was independently associated with LVMI in women (β=0.27, P=0.02). Multivariate logistic regression analysis also revealed that diabetes mellitus (odds ratio (OR), 4.41; P=0.01) was associated with LVH in men, whereas age (OR, 1.13; P<0.01), hypertension (OR, 7.38; P=0.03) and SUA (OR, 1.91; P=0.03) were associated with LVH in women. In female CKD patients, SUA levels were associated with LVMI and LVH, whereas there was no association in male patients. These observations suggest that an association between SUA levels and the development of cardiac hypertrophy is more likely in women than in men.
Collapse
|
62
|
Motoki T, Fukuda M, Nakano T, Matsukage S, Fukui A, Akiyoshi S, Hayashi YK, Ishii E, Nishino I. Fatal hepatic hemorrhage by peliosis hepatis in X-linked myotubular myopathy: a case report. Neuromuscul Disord 2013; 23:917-21. [PMID: 24011703 DOI: 10.1016/j.nmd.2013.06.008] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2012] [Revised: 05/04/2013] [Accepted: 06/11/2013] [Indexed: 12/30/2022]
Abstract
We report a 5-year-old boy with X-linked myotubular myopathy complicated by peliosis hepatis. At birth, he was affected with marked generalized muscle hypotonia and weakness, which required permanent ventilatory support, and was bedridden for life. He died of acute fatal hepatic hemorrhage after using a mechanical in-exsufflator. Peliosis hepatis, defined as multiple, variable-sized, cystic blood-filled spaces through the liver parenchyma, was confirmed by autopsy. To avoid fatal hepatic hemorrhage by peliosis hepatis, routine hepatic function tests and abdominal imaging tests should be performed for patients with X-linked myotubular myopathy, especially at the time of using artificial respiration.
Collapse
|
63
|
Saito S, Teshima Y, Takahashi N, Kondo H, Fukui A, Aoki K, Shinohara T, Nakagawa M, Hara M, Saikawa T. Glucose fluctuations increase inducibility of atrial fibrillation in diabetic rats. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht309.p4265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
64
|
Fukui A, Ohta K, Nishi H, Shigeishi H, Tobiume K, Takechi M, Kamata N. Interleukin-8 and CXCL10 expression in oral keratinocytes and fibroblasts via Toll-like receptors. Microbiol Immunol 2013; 57:198-206. [DOI: 10.1111/1348-0421.12022] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2012] [Revised: 11/27/2012] [Accepted: 12/19/2012] [Indexed: 11/28/2022]
|
65
|
Matsuda C, Tamagawa H, Nishikawa K, Deguchi T, Kawata J, Iwase K, Takagi M, Fukui A, Nezu R, Tanaka Y. [Study of tolerability of capecitabine in postoperative adjuvant chemotherapy in colon cancer]. Gan To Kagaku Ryoho 2013; 40:327-330. [PMID: 23507593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
OBJECTIVE Based on the results of the X-ACT study, capecitabine has become one of the standard postoperative adjuvant chemotherapies for colon cancer. However, few studies of tolerability have been conducted in Japan. METHOD In this study, we retrospectively examined treatment continuation, and the adverse events that occurred during eight courses of postoperative adjuvant chemotherapy with capecitabine, in 34 patients with colon cancer who had undergone curative resection. RESULT The completion rate for eight courses of treatment with capecitabine was 79. 4%(27 of 34 subjects), the median relative dose intensity was 94. 4%(13% to 106%), and the proportion of subjects with relative dose intensity B 60% was 82. 4%(28 of 34 subjects). The following Grade 3 or higher adverse events were reported: hand-foot syndrome, in 11. 8%(4 of 34 subjects); mucositis oral, in 2. 9%(1 of 34 subjects); diarrhea, in 2. 9%(1 of 34 subjects); and glans penis ulcer, in 2. 9%(1 of 34 subjects). CONCLUSION In our hospital, a high rate of capecitabine treatment continuation comparable to that reported in the X-ACT study was obtained, suggesting that capecitabine adjuvant chemotherapy would be well tolerated in clinical practice as well.
Collapse
|
66
|
Nishikawa K, Iwase K, Aono T, Yoshida H, Nomura M, Tamagawa H, Matsuda C, Deguchi T, Kawada J, Higashi S, Umeda S, Deguchi K, Fushimi H, Takagi M, Fukui A, Tanaka Y. [Efficacy of capecitabine/cisplatin chemotherapy after failure of all conventional therapies in patients with advanced gastric cancer]. Gan To Kagaku Ryoho 2013; 40:57-60. [PMID: 23306918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
There is no standard therapy for advanced gastric cancer patients who had already failed treatment with major anti-cancer drugs including fluoropyrimidine, cisplatin, taxans, and irinotecan. We report the results of treatment with capecitabine and cisplatin(XP)after the failure of all other conventional therapies. A total of five advanced gastric cancer patients were treated. The median age was 59 years(range, 46-76); there were 3male and 2 female patients; performance status was 0/1/2: 2/2/ 1 patients, respectively. The median duration from start of first-line chemotherapy to XP was 653 days(range, 372-1,107). Three patients were treated after fourth-line therapy and two patients after fifth-line therapy. All of the patients had received S-1, cisplatin, irinotecan, paclitaxel, and docetaxel previously. Patients received 80mg/m2 of cisplatin intravenously on day 1, and 1,000mg/m2 of capecitabine orally twice a day from day 1 to day 14 followed by a 7-day rest period. Treatment courses were between 2 to 5. Median time to progression was 107 days. Median overall survival was 245 days. One PR and one SD were reported. All reported adverse events were manageable. XP is considered one of the effective regimens for advanced gastric cancer after all conventional therapies have failed.
Collapse
|
67
|
Kawada J, Iwase K, Deguchi K, Higashi S, Deguchi T, Matsuda C, Tamagawa H, Omori K, Nishikawa K, Nomura M, Takagi M, Fukui A, Tanaka Y. [Analysis of combination chemotherapy with docetaxel and nedaplatin for esophageal cancer]. Gan To Kagaku Ryoho 2012; 39:2095-2097. [PMID: 23267988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
PURPOSE There is no standard second line regimen for metastatic or recurrent esophageal cancer. We investigated the feasibility of combination chemotherapy with Docetaxel (DOC) and Nedaplatin (CDGP) as a second-line regimen for metastatic or recurrent esophageal cancer. MATERIALS AND METHODS Patients received DOC (60 mg/m2 intravenously) on day 1 and subsequently CDGP(70 mg/m2 intravenously) on day 1 of each 4-week period thereafter. We analyzed the toxicity and efficacy in 9 patients treated with combination chemotherapy with DOC and CDGP. RESULT The observed Grade 3-4 toxicities were neutropenia and anemia. Three patients had stable disease and 6 patients had progressive disease. The median progression free survival and overall survival were 4.3 and 8.1 months, respectively. CONCLUSION Combination chemotherapy with DOC and CDGP is considered a feasible second line regimen for metastatic or recurrent esophageal cancer.
Collapse
|
68
|
Fukui A, Fukuhara R, Kimura H, Fujii S, Mizunuma H. Safe and effective first line therapy for women with unexplained infertility in real clinic practice. Fertil Steril 2012. [DOI: 10.1016/j.fertnstert.2012.07.650] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
69
|
|
70
|
Yamaguchi E, Fukui A, Funamizu A, Yokota M, Fukuhara R, Mizunuma H. Sexual intercourse with pyospermia decreases uterine CD16-/CD56 bright natural killer cells in women with infertility. J Reprod Immunol 2012. [DOI: 10.1016/j.jri.2012.03.279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
71
|
Fukui A, Funamizu A, Yokota M, Kamoi M, Fukuhara R, Yamaguchi E, Mizunuma H. Intravenous immunoglobulin for women with recurrent pregnancy loss and elevated NK cell cytotoxicity. J Reprod Immunol 2012. [DOI: 10.1016/j.jri.2012.03.312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
72
|
Taniguchi Y, Takahashi N, Fukui A, Nagano-Torigoe Y, Thuc LC, Teshima Y, Shinohara T, Wakisaka O, Ooie T, Murozono Y, Yufu K, Nakagawa M, Hara M, Yoshimatsu H, Saikawa T. Candesartan restored cardiac Hsp72 expression and tolerance against reperfusion injury in hereditary insulin-resistant rats. Cardiovasc Res 2011; 92:439-48. [DOI: 10.1093/cvr/cvr254] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
73
|
Nishio S, Ushijima K, Fukui A, Tsuda N, Kawano K, Ota S, Sonoda G, Yamaguchi T, Kage M, Kamura T. 8042 POSTER Nuclear Y-box Binding Protein-1 Expression, a Predictive Marker of Prognosis, Is Correlated With Activated Signal Transducer and Activator of Transcription-3 Expression and Survival in Cervical Squamous-cell Carcinoma. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72130-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
74
|
Fukui A. Uterine and circulating natural killer cells and their roles in women with recurrent pregnancy losses, implantation failures or preeclampsia. J Reprod Immunol 2010. [DOI: 10.1016/j.jri.2010.08.015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
75
|
Ohta K, Nishi H, Fukui A, Shigeishi H, Takechi M, Kamata N. CX3CL1 expression induced by Candida albicans in oral fibroblasts. ACTA ACUST UNITED AC 2010; 60:179-85. [DOI: 10.1111/j.1574-695x.2010.00734.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|